Debt-to-equity in % of Evoke Pharma Inc from Q2 2014 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Evoke Pharma Inc quarterly Debt-to-equity history and change rate from Q2 2014 to Q3 2025.
  • Evoke Pharma Inc Debt-to-equity for the quarter ending 30 Sep 2025 was 218%, a 54% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Evoke Pharma Inc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 218% -257% -54% 30 Sep 2025
Q2 2025 196% -1162% -86% 30 Jun 2025
Q1 2025 202% -5942% -97% 31 Mar 2025
Q4 2024 220% +4623% 31 Dec 2024
Q3 2024 475% -84% -15% 30 Sep 2024
Q2 2024 1359% +1098% +421% 30 Jun 2024
Q1 2024 6144% +5982% +3681% 31 Mar 2024
Q4 2023 -4403% -4563% -2855% 31 Dec 2023
Q3 2023 559% +399% +249% 30 Sep 2023
Q2 2023 261% +99% +61% 30 Jun 2023
Q1 2023 163% -38% -19% 31 Mar 2023
Q4 2022 160% -7.4% -4.5% 31 Dec 2022
Q3 2022 160% -117% -42% 30 Sep 2022
Q2 2022 162% -352% -69% 30 Jun 2022
Q1 2022 201% -1602% -89% 31 Mar 2022
Q4 2021 167% 31 Dec 2021
Q3 2021 278% 30 Sep 2021
Q2 2021 514% 30 Jun 2021
Q1 2021 1802% 31 Mar 2021
Q4 2018 30% -117% -80% 31 Dec 2018
Q3 2018 57% -77% -58% 30 Sep 2018
Q2 2018 121% +14% +13% 30 Jun 2018
Q1 2018 143% -22% -13% 31 Mar 2018
Q4 2017 147% -163% -53% 31 Dec 2017
Q3 2017 134% -197% -60% 30 Sep 2017
Q2 2017 107% -202% -65% 30 Jun 2017
Q1 2017 166% -14% -7.7% 31 Mar 2017
Q4 2016 309% +182% +142% 31 Dec 2016
Q3 2016 331% +232% +235% 30 Sep 2016
Q2 2016 309% +245% +383% 30 Jun 2016
Q1 2016 180% +142% +383% 31 Mar 2016
Q4 2015 128% +103% +408% 31 Dec 2015
Q3 2015 99% +81% +472% 30 Sep 2015
Q2 2015 64% +45% +231% 30 Jun 2015
Q1 2015 37% 31 Mar 2015
Q4 2014 25% 31 Dec 2014
Q3 2014 17% 30 Sep 2014
Q2 2014 19% 30 Jun 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.